VCEL
Price:
$44.37
Market Cap:
$2.18B
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar ...[Read more]
Industry
Biotechnology
IPO Date
1997-02-04
Stock Exchange
NASDAQ
Ticker
VCEL
According to Vericel Corporation’s latest financial reports and current stock price. The company's current ROE is 0.35%. This represents a change of 264.79% compared to the average of 0.10% of the last 4 quarters.
The mean historical ROE of Vericel Corporation over the last ten years is -31.30%. The current 0.35% ROE has changed -101.11% with respect to the historical average. Over the past ten years (40 quarters), VCEL's ROE was at its highest in in the December 2020 quarter at 9.10%. The ROE was at its lowest in in the March 2017 quarter at -63.07%.
Average
-31.30%
Median
-8.32%
Minimum
-79.19%
Maximum
2.13%
Discovering the peaks and valleys of Vericel Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 98.28%
Maximum Annual ROE = 2.13%
Minimum Annual Increase = -305.46%
Minimum Annual ROE = -79.19%
Year | ROE | Change |
---|---|---|
2023 | -1.41% | -83.79% |
2022 | -8.69% | 98.28% |
2021 | -4.38% | -305.46% |
2020 | 2.13% | -129.96% |
2019 | -7.12% | -10.55% |
2018 | -7.96% | -89.62% |
2017 | -76.69% | -3.15% |
2016 | -79.19% | 7.24% |
2015 | -73.84% | 32.11% |
2014 | -55.89% | -86.07% |
The current ROE of Vericel Corporation (VCEL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.83%
5-year avg
-3.89%
10-year avg
-31.30%
Vericel Corporation’s ROE is greater than CollPlant Biotechnologies Ltd. (-65.98%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Merus N.V. (-45.38%), greater than Century Therapeutics, Inc. (-65.37%), greater than Chimerix, Inc. (-46.35%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Mereo BioPharma Group plc (-63.39%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than IDEAYA Biosciences, Inc. (-19.42%), greater than Syndax Pharmaceuticals, Inc. (-57.42%), greater than Xencor, Inc. (-28.21%), greater than REGENXBIO Inc. (-68.21%), greater than Crinetics Pharmaceuticals, Inc. (-62.63%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Pliant Therapeutics, Inc. (-41.05%), greater than Dyne Therapeutics, Inc. (-68.85%), less than Cytokinetics, Incorporated (196.01%), greater than Revolution Medicines, Inc. (-34.57%), greater than Blueprint Medicines Corporation (-47.66%), greater than Relay Therapeutics, Inc. (-43.66%),
Company | ROE | Market cap |
---|---|---|
-65.98% | $42.50M | |
-44.73% | $2.25B | |
-45.38% | $3.51B | |
-65.37% | $106.74M | |
-46.35% | $88.74M | |
-22.40% | $1.49B | |
32.93% | $89.59M | |
-63.39% | $616.59M | |
-39.58% | $599.50M | |
-19.42% | $2.53B | |
-57.42% | $1.61B | |
-28.21% | $1.50B | |
-68.21% | $432.95M | |
-62.63% | $5.12B | |
-57.89% | $689.69M | |
-41.05% | $881.01M | |
-68.85% | $2.89B | |
196.01% | $6.06B | |
-34.57% | $9.33B | |
-47.66% | $5.84B | |
-43.66% | $950.40M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vericel Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Vericel Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Vericel Corporation's ROE?
How is the ROE calculated for Vericel Corporation (VCEL)?
What is the highest ROE for Vericel Corporation (VCEL)?
What is the 3-year average ROE for Vericel Corporation (VCEL)?
What is the 5-year average ROE for Vericel Corporation (VCEL)?
How does the current ROE for Vericel Corporation (VCEL) compare to its historical average?